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Abstract Platelets secrete platelet-derived growth factor
(PDGF) and vascular endothelial growth factor (VEGF) upon
stimulation. We have demonstrated that platelets have function-
ally active PDGF K-receptors, a transmembrane tyrosine kinase
involved in negative feedback regulation. Here we demonstrate
the presence of the related VEGF receptors fms-like tyrosine
kinase-1 and kinase-insert domain region on human platelets.
VEGF itself did not cause platelet aggregation. However,
addition of exogenous VEGF to SFRLLN or thrombin-
stimulated platelets potentiated platelet aggregation. Moreover,
thrombin-induced phosphoinositide 3-kinase and mitogen-acti-
vated protein kinase activity were enhanced in the presence of
VEGF. ß 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Platelet adhesion to endothelial surfaces in response to vas-
cular injury or during pathophysiological conditions results in
secretion of substances from platelet dense granules (e.g.
ADP, ATP and serotonin), lysosomes (acid hydrolases) and
K granules (proteins only, including coagulation factors, ¢-
brinogen, platelet-derived growth factor (PDGF), transform-
ing growth factor-L (reviewed in [1]). More recently it has
been shown that platelets also secrete vascular endothelial
growth factor (VEGF) during platelet activation [2,3].
VEGF is a key regulator of angiogenesis, the formation of
new capillaries from pre-existing vessels, and for the progres-
sion of several disease states including tumor growth and
metastasis [4,5].
VEGF-A is a strong inducer of vascular permeability and a
potent mitogen for endothelial cells [5]. It binds to and exerts
its biological e¡ect through two tyrosine kinase receptors,
VEGF receptor-1 (VEGFR1) (Flt-1, fms-like tyrosine kinase)
and VEGFR2 (KDR, kinase-insert domain region) [5,6]. The
VEGFRs are structurally related to type III transmembrane
tyrosine kinase receptors belonging to the PDGF receptor
family [5].
We previously demonstrated that human platelets have
functionally active PDGF K-receptors, but not L-receptors
[7], and that an autocrine inhibition pathway is transduced
through such tyrosine kinase receptors during platelet activa-
tion [7,8]. In this study we give evidence for the expression of
the related Flt-1 and KDR receptors in platelets. Moreover,
we show here that VEGF has a potentiating e¡ect on platelet
activation.
2. Materials and methods
2.1. Materials
Recombinant human VEGF was purchased from Pharmingen (San
Diego, CA, USA). Monoclonal anti-VEGFR1 (Flt-1 receptor) and
general laboratory reagents were supplied by Sigma (St. Louis, MO,
USA). The VEGFR2 (KDR receptor) speci¢c antiserum was kindly
provided by Prof. Carl-Henrik Heldin (Ludwig Institute for Cancer
Research, Uppsala, Sweden). Thrombin was purchased from Parke-
Davis (Morris Plains, NJ). Prof. Nils Olav Solum (Rikshospitalet,
Oslo, Norway) generously provided the synthetic thrombin receptor
agonist peptide Ser-Phe-Arg-Leu-Leu-Asn (SFLLRN). Mitogen-acti-
vated protein kinase (MAPK) detection kit was from Upstate Bio-
technology (Lake Placid, NY, USA). Protein A^Sepharose and
Sepharose CL-2B were from Pharmacia Biotech, Sweden. [32P]-
Orthophosphate ([32P]Pi) and [Q-32P]ATP were from Amersham
(Amersham, UK).
2.2. Methods
2.2.1. Platelet isolation, labelling and incubation. Platelet-rich plas-
ma was prepared from fresh human venous blood anticoagulated with
acid citrate dextrose obtained at the blood bank, Haukeland Hospital,
Bergen, Norway. Achievement of highly marked [32P]phos-
phoinositides and isolation of platelet by gel-¢ltration was done as
previously described [9]. Aggregation of gel-¢ltered platelets was mea-
sured in a chronolog dual channel aggregation module interfaced to a
PC (Chrono-log Whole Blood-Lumi ionized calcium aggregometer,
Havertown, PA, USA).
2.2.2. Extraction and analysis of 3-phosphorylated glycero-
phosphoinositides. Extraction of 3-phosphorylated glycerophospho-
inositides was done as described previously [10]. The radioactive frac-
tions of phosphatidylinostol 3,4,5-trisphosphate (PtdIns(3,4,5)P3)
were deacylated and subjected to high performance liquid chromatog-
raphy eluted with a 0^2 M gradient of (NH4)3PO4 (pH 3.8) according
to Auger et al. [11]. The radioactive peak was detected directly in the
eluate by Cerenkov counting. The output from the monitor was re-
corded online with a standard PC.
2.2.3. In vitro immune complex MAPK kinase assay. MAPK im-
munoprecipitation kinase assay was carried out according to the man-
ufacturer’s instructions (Upstate Biotechnology). Brie£y, platelets
were solubilized in lysis bu¡er (50 mM Tris, pH 7.5, 1 mM EDTA,
1 mM EGTA, 0.5 mM Na3VO4, 0.1% 2-mercaptoethanol, 1% Triton
X-100, 50 mM sodium £uoride, 5 mM sodium pyrophosphate, 10 mM
sodium L-glycerol phosphate, 0.1 mM phenylmethylsulfonyl £uoride
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(PMSF), 1 Wg/ml of aprotinin, pepstatin and leupeptin, and 1 WM
microcystin) and MAPK was immunoprecipitated with anti-rat
MAPK-R2 (cross-reactive with human p42/erk1 and p42/erk2). Pro-
tein A^Sepharose CL-4B (Pharmacia Biotech) was used to collect the
immune complexes. The protein A^Sepharose/MAPK immune com-
plex kinase assay was performed in 40 Wl assay dilution bu¡er (20 mM
morpholinopropanesulfonic acid, 25 mM L-glycerol phosphate, 5 mM
EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol) contain-
ing MAPK inhibitor cocktail, MAPK substrate cocktail (myelin basic
protein), and 10 WCi [Q-32P]ATP, for 20 min in a 30‡C shaking incu-
bator. The protein A^Sepharose/MAPK immune complex was pel-
leted and 30 Wl of the supernatant was spotted onto the center of
P81 phosphocellulose paper squares. The assay squares were washed
three times in 0.75% phosphoric acid and once in acetone. Finally, the
radioactivity of the assay squares was determined by liquid scintilla-
tion counting.
2.2.4. In vitro immune complex VEGFR kinase assay. Platelets
were solubilized in lysis bu¡er (0.5 M NaCl, 0.02 M Tris^HCl, pH
7.4, 0.5% Triton X-100, 1% Trasylol, 1 mM PMSF, 1 mM dithiothrei-
tol) for 20 min at 4‡C. The lysates were centrifuged at 13 000Ug for
15 min and the supernatants were then subjected to immunoprecipi-
tation with anti-VEGFR1 (Flt-1 receptor) or anti-VEGFR2 (KDR
receptor) speci¢c antiserum for 2 h. Protein A^Sepharose CL-4B
was used to collect the immune complexes. Kinase assay were per-
formed in 35 Wl of 20 mM HEPES, pH 7.5, 10 mM MnCl2, 1 mM
dithiothreitol, containing 10 WCi [Q-32P]ATP for 30 min at room tem-
perature. After eluting the immune complexes by heating the beads at
95‡C for 4 min in 35 Wl sample bu¡er (4% SDS, 2% mercaptoethanol,
0.2 M Tris^HCl, pH 8.8, 0.5 M sucrose, 5 mM EDTA, 0.01% bro-
mophenol blue), the samples were subjected to electrophoresis on a 5^
15% gradient reducing SDS^polyacrylamide gel electrophoresis
(PAGE). The 32P-labelled proteins were detected by autoradiography.
3. Results
3.1. Human platelets express Flt-1 and KDR receptors
We have previously reported that human platelets have
functionally active PDGF K-receptors, but not L-receptors
[7]. The related c-Kit receptor is also found in human platelets
[12]. To determine whether platelets also contain VEGFRs,
which are members of the same subfamily of type III trans-
membrane tyrosine kinase as the PDGF and c-Kit receptors,
human platelets were preincubated with recombinant VEGF
(250 ng/ml) or vehicle for 1 min at 37‡C before incubation
with thrombin (0.1 U/ml) or vehicle for a further 5 min. Plate-
lets were lysed and immunoprecipitated with antisera speci¢c
for the Flt-1 or KDR receptors. The precipitates were washed
and incubated with [Q-32P]ATP before SDS^PAGE. As shown
in Fig. 1A, stimulation of platelets by thrombin in the pres-
ence of VEGF produced a heavily phosphorylated protein of
approx. 180 kDa (Fig. 1A, lane 4), corresponding to the Flt-1
receptor, which was immunoprecipitated with monoclonal
anti-Flt-1. VEGF alone (Fig. 1A, lane 2) showed small or
no e¡ect on the autophosphorylation of the 180 kDa protein.
Thus, active VEGF-binding Flt-1 receptors only seem to be
exposed on the platelet surface after stimulation of the plate-
lets with thrombin. The KDR antiserum identi¢ed a doublet
of approx. 190 and 170 kDa (Fig. 1B). The 190 kDa and 170
kDa proteins correspond to glycosylated and non-glycosylat-
ed form of the KDR as recently described [13]. The relative
high amount of radioactivity in the absence of added VEGF
suggests that the putative KDR receptor is constitutively ty-
rosine phosphorylated. Ligand-independent receptor auto-
phosphorylation has previously been reported for both Flt-1
and KDR [13,14]. It is also possible that this phosphorylation
partly is caused by dimerization of the receptors by the KDR
antiserum as previously observed for the PDGF receptors
[15] ; however, platelets coincubated with VEGF and throm-
bin showed markedly increased tyrosine phosphorylation of
the putative KDR receptor (Fig. 1B, lanes 3 and 5).
3.2. VEGF enhances thrombin- and SFLLRN-induced
platelet activation
In order to investigate whether VEGF responsive tyrosine
kinase receptors could modulate platelet activation, we per-
formed platelet aggregation studies. Fig. 2A shows that the
(0.05 U/ml) thrombin-induced platelet aggregation was en-
hanced by addition of VEGF (250 ng/ml). When platelets
were incubated with a SFLLRN (5 WM) concentration too
Fig. 1. Human platelets express functionally active KDR and Flt-1
receptors. Human platelets were preincubated with 250 ng/ml
VEGF or vehicle for 1 min before activation with thrombin for
5 min at 37‡C. Platelet lysates were immunoprecipitated with antise-
rum speci¢c for the Flt-1 (A) or the KDR (B) receptors and protein
A^Sepharose; the receptor immune complexes were then subjected
to an in vitro protein kinase assay by incubation with [Q-32P]ATP.
32P-labelled proteins were separated by SDS^PAGE and detected by
autoradiography. Flt-1 (180 kDa) and KDR (200 and 170 kDa) re-
ceptor bands are indicated by arrows.
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low to induce platelet aggregation, addition of VEGF (250 ng/
ml) induced platelet reversible aggregation (Fig. 2B). VEGF
by itself failed to induce platelet aggregation (data not
shown). Thus, VEGF enhanced the thrombin-induced platelet
aggregation.
3.3. E¡ect of VEGF on thrombin-induced phosphoinositide
3-kinase (PI3K) and MAPK activity
PI3K and MAPK signalling pathways have been reported
to be crucial elements in VEGF-activated endothelial cell sur-
vival and proliferation [4,16^18]. We therefore decided to
study if VEGF had any e¡ects on these signalling molecules
in platelets. For measurement of the PI3K product
PtdIns(3,4,5)P3, [32P]Pi-labelled platelets were preincubated
with VEGF (250 ng/ml) or vehicle for 1 min before stimula-
tion with thrombin (0.04 U/ml). VEGF alone had no e¡ect on
synthesis of PtdIns(3,4,5)P3, however, the thrombin-induced
synthesis of PtdIns(3,4,5)P3 was markedly increased in the
presence of VEGF (Fig. 3).
To investigate if VEGF had any e¡ect on platelet MAPK,
we immunoprecipitated MAPK1/erk1 and MAPK2/erk2 from
VEGF and thrombin-stimulated platelets and subsequently
measured the activity of the MAPKs in the immune complex.
As shown in Fig. 3, VEGF (250 ng/ml) clearly enhanced (0.1
U/ml) thrombin-induced MAPK activity. Platelet incubated
Fig. 2. Stimulatory e¡ect of VEGF on thrombin- and SFLLRN-in-
duced platelet aggregation. Gel-¢ltered platelets were stirred at 1000
rpm measured in a Chronolog dual channel aggregation module in-
terfaced to a PC. Arrows show additions. A: Thrombin (0.04
U/ml)+vehicle versus thrombin (0.04 U/ml)+VEGF (250 ng/ml);
B: SFLLRN (40 WM)+vehicle versus SFRLLN (40 WM)+VEGF
(250 ng/ml).
Table 1
VEGF enhance thrombin-induced MAPK activity
MAPK activity (cpm)
Vehicle 2 832 þ 316
VEGF 5 362 þ 2 010
Thrombin 12 997 þ 3 276
Thrombin+VEGF 22 630 þ 3 722
Gel-¢ltered platelets were preincubated with 250 ng/ml VEGF or ve-
hicle for 5 min before activation with thrombin (0.1 U/ml) for 5 min
at 37‡C. Platelet lysates were immunoprecipitated with anti-MAPK-
R2. The immunoprecipitated MAPK was used to phosphorylate
myelin basic protein in vitro as described in Section 2. The data are
representative of two separate experiments, bars show mean þ
S.E.M.
Fig. 3. Thrombin-induced synthesis of PtdIns(3,4,5)P3 is augmented
by VEGF. Gel-¢ltered platelets were stirred at 1000 rpm in a two-
channel aggregometer at 37‡C with thrombin (0.04 U/ml) or VEGF
(250 ng/ml) plus thrombin together. VEGF was added 10 s after
stimulation with thrombin. Radiolabelled deacylated phospholipids
were analyzed by high performance liquid chromatography as de-
scribed in Section 2. The data are representative of two separate ex-
periments, bars show mean þ S.E.M.
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with VEGF alone showed a small increase in MAPK activity
(Table 1).
4. Discussion
In this study we show by immune complex kinase assay that
platelets also have functional Flt-1 and KDR receptors. En-
hanced tyrosine phosphorylation of the putative Flt-1 and
KDR receptors were only observed on platelets that where
coactivated with VEGF and thrombin. Thus, the platelet
VEGFRs seem to be cryptic receptors which become exposed
on the platelet membrane during platelet activation. Consis-
tent with this hypothesis, we found no e¡ect on platelet ag-
gregation when platelets were incubated with VEGF alone.
However, addition of VEGF to SFLLRN- and thrombin-
stimulated platelets clearly potentiated platelet aggregation.
In concordance with our ¢ndings, the presence of Flt-1
mRNA has just been identi¢ed in platelets [19].
Regarding the above discussion, the granulocyte colony-
stimulating factor and stem cell factor (c-Kit) only potentiate
platelet activation induced by physiological agonists, and have
no e¡ect by themselves [12,20]. An active, ligand binding c-Kit
receptor was only observed after stimulation of platelets with
agonist. Ligation of the tyrosine kinase receptors c-Kit [12],
KDR and Flt-1 (present study) are all found to have a stim-
ulatory e¡ect on human platelets. In contrast, the PDGF K-
receptor transduces inhibitory signals for platelet activation
[7,8,21]. However, exposure of speci¢c PDGF binding sites
on the platelet membrane has been shown to appear only after
platelets activation [21]. Thus, the requisite for platelet pre-
stimulation for exposure of a conformational active ligand
binding receptor seems to be a common feature for the trans-
membrane tyrosine kinase receptors on platelets.
PI3K and MAPK are key players in VEGF-induced endo-
thelial cell survival and proliferation [4,16^18]. We show here
that VEGF increases the thrombin-induced synthesis of the
PI3K product PtdIns(3,4,5)P3. Moreover, VEGF markedly
enhanced the MAPK activity in thrombin-stimulated plate-
lets. Thus, platelets VEGFRs seem to activate the same signal-
ling pathways as the endothelial Flt-1 and KDR receptors.
It has recently been reported that cancer patients with soft
tissue sarcomas show high VEGF expression and the presence
of activated platelets within the tumor vasculature [22]. Ver-
heul et al. [23] recently reported that VEGF-stimulated endo-
thelial cells promoted adhesion of non-activated platelets.
Platelet adhesion was found to be dependent on VEGF-in-
duced endothelial tissue factor (TF) expression and subse-
quent generation of thrombin from prothrombin by the acti-
vated coagulation cascade. In addition, it has been shown that
thrombin-activated platelet secretes proangiogenic VEGF
[2,3]. Our results showing a stimulatory e¡ect of exogenously
added VEGF on thrombin-induced platelet activation, suggest
that, in addition to its major role as an angiogenic factor,
endogenously secreted platelet VEGF may function as a pos-
itive feedback regulator during platelet activation.
VEGF has many vascular e¡ects. It stimulates production
of the PGI2 and NO in the endothelium [5], agents that coun-
teract platelet activation. Conversely, VEGF activates TF
which initiates the intrinsic coagulation cascade, culminating
in production of thrombin, a potent platelet agonist. The
secretion of VEGF from platelets also points to a role of
platelets in angiogenesis, which has both physiological (heal-
ing) and pathological roles (tumor growth).
In conclusion, the present work shows that VEGF, in ad-
dition to the known e¡ects listed above, also has a potentiat-
ing e¡ect on platelet activation. Obviously, VEGF is involved
in the ¢ne-tuning of platelet activation both through its auto-
crine platelet behavior and through VEGF^endothelial cell
interactions.
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